Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing

BMC Geriatrics

Systematic Review

Ilkka Kunnamo¹  Christina Sommerauer²  Andreas Sönnichsen²  Lisa Schlender²  Barbara Faller²  Anna Renom-Guiteras³  Thekraiat Al Qur’an⁴  Adrine Woodham⁵  David Reeves⁵  Charles Adeniji⁵  Yolanda V. Martinez⁵ 

[1] Duodecim Medical Publications Ltd, Helsinki, Finland;Institut für Allgemeinmedizin und Familienmedizin, UWH, Witten, Germany;Institut für Allgemeinmedizin und Familienmedizin, UWH, Witten, Germany;Department of Geriatrics, University Hospital Parc de Salut Mar, Barcelona, Spain;Institut für Allgemeinmedizin und Familienmedizin, UWH, Witten, Germany;Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan;NIHR School for Primary Care Research, University of Manchester, Manchester, UK;

关键词: Systematic review;    Metformin;    Type 2 diabetes mellitus;    Inappropriate prescribing;    Older people;    Elder;    Elderly;   

DOI  :  10.1186/s12877-017-0574-5

来源: Springer

【 摘 要 】

BackgroundMetformin is usually prescribed as first line therapy for type 2 diabetes mellitus (DM2). However, the benefits and risks of metformin may be different for older people. This systematic review examined the available evidence on the safety and efficacy of metformin in the management of DM2 in older adults. The findings were used to develop recommendations for the electronic decision support tool of the European project PRIMA-eDS.MethodsThe systematic review followed a staged approach, initially searching for systematic reviews and meta-analyses first, and then individual studies when prior searches were inconclusive. The target population was older people (≥65 years old) with DM2. Studies were included if they reported safety or efficacy outcomes with metformin (alone or in combination) for the management of DM2 compared to placebo, usual or no treatment, or other antidiabetics. Using the evidence identified, recommendations were developed using GRADE methodology.ResultsFifteen studies were included (4 intervention and 11 observational studies). In ten studies at least 80% of participants were 65 years or older and 5 studies reported subgroup analyses by age. Comorbidities were reported by 9 studies, cognitive status was reported by 4 studies and functional status by 1 study. In general, metformin showed similar or better safety and efficacy than other specific or non-specific active treatments. However, these findings were mainly based on retrospective observational studies. Four recommendations were developed suggesting to discontinue the use of metformin for the management of DM2 in older adults with risk factors such as age > 80, gastrointestinal complaints during the last year and/or GFR ≤60 ml/min.ConclusionsOn the evidence available, the safety and efficacy profiles of metformin appear to be better, and certainly no worse, than other treatments for the management of DM2 in older adults. However, the quality and quantity of the evidence is low, with scarce data on adverse events such as gastrointestinal complaints or renal failure. Further studies are needed to more reliably assess the benefits and risks of metformin in very old (>80), cognitively and functionally impaired older people.

【 授权许可】

CC BY   
© The Author(s). 2017